Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ESMO 2023: TROPION-Breast01 And -Lung01 Studies Breathe Life Into Dato-DXd

Executive Summary

The future for AstraZeneca/Daiichi Sankyo’s TROP2-targeted ADC candidate Dato-DXd is looking more positive after details of their TROPION-Lung01 and TROPION-Breast01 Phase III studies were presented at ESMO.

You may also be interested in...

Big Pharma's Practice-Changing Data Dominates At ESMO

Unseasonal showers hit Madrid during the European Society for Medical Oncology congress where most of the major data readouts came from the biggest players in the sector rather than ambitious biotechs. Here, In Vivo looks at three must-see presentations from the prestigious meeting.

Daiichi In Massive $22bn Global Deal With Merck & Co For Three ADCs

The two firms will co-develop and co-commercialize three Daiichi ADCs globally outside Japan in a deal the Japanese firm said would allow “more aggressive development plans targeting broader patient populations.” 

Promising Early Results For AZ And Daiichi’s Dato-DXd In Breast Cancer – But How Soon Can They File?

Once again choosing their words carefully, the partners talk only of ‘plans’ to file as regulators will first have to clarify when overall survival data will be required for the new antibody-drug conjugate in breast cancer.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts